Imperial and Bayer use AI in the development of new drugs for heart disease

imperial and Bayer Pharmaceuticals are working together to explore how artificial intelligence (AI) can be used to accelerate the development of new drugs for heart disease.The partner plans to develop machine learning tools to analyze 3D heart imaging, as well as genetic information, as part of a new approach to drug discovery.2018 is the year when companies adopt artificial intelligence and machine learning, ushering in an era of faster, cheaper and more effective drug development.The new partnership will use data from biobank UK, a national health resource that contains a wealth of information on 500,000 people in the UK, to enable them to identify ways to treat heart disease that could provide new targets.Dr Declan O'Regan, from the MRC London Institute of Medical Sciences, said: "Artificial intelligence has the potential to change our understanding of heart disease and accelerate the discovery of new treatments. Our partnership with Bayer will use state-of-the-art computer vision algorithms and advanced statistical techniques to understand the relationship between genetic variation and heart movement using data collected by Biobank UK.“ This academic-industrial partnership is achieved through innovative interdisciplinary research that connects imaging, machine learning, and clinical pharmacology, and reflects the Empire's dedication to driving the practical application of artificial intelligence in medical research. However seven million people in the UK alone suffer from heart disease and circulatory diseases, of which cardiovascular disease causes a quarter of deaths. (Compiled by this web)